Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) has launched the EasyFuse™ Dynamic Compression System, a new foot and ankle staple made from nitinol, known for its strength and shape recovery. This system aims to enhance surgical efficiency by simplifying procedures and reducing waste in operating rooms. The EasyFuse system features an extra wide staple bridge for consistent strength, universal sterile instrumentation to cut down on complexity, and an intuitive inserter for easy deployment. This innovation is expected to improve patient outcomes and expand options for surgeons.
Stryker (NYSE:SYK) has announced the appointment of Jason Beach as the new Vice President of Investor Relations, effective July 1, 2022. Beach, who joined Stryker in 2018, previously held the role of Vice President of Finance in the Instruments division, where he contributed to significant growth and successful acquisitions. He will report to Glenn Boehnlein, the Chief Financial Officer. Meanwhile, Preston Wells will transition to Vice President, Group Chief Financial Officer for Orthopaedics and Spine. This move is part of Stryker's strategy to enhance its investor relations capabilities.
Stryker (NYSE: SYK) announced leadership changes on May 4, 2022, with Sherilyn S. McCoy named as the new Lead Independent Director, replacing Allan C. Golston. McCoy joined the board in 2018, previously chairing the Governance and Nominating Committee since 2019. Golston, a board member since 2011, has served as Lead Independent Director since 2016. Mary K. Brainerd will replace McCoy as Chair of the Governance and Nominating Committee. Stryker emphasizes diversity and effective governance, supporting better healthcare outcomes.
Stryker (NYSE:SYK) announced a quarterly dividend of $0.695 per share, payable on July 29, 2022, to shareholders of record on June 30, 2022. This marks a 10.3% increase compared to the previous year while remaining unchanged from the last quarter. Stryker is a leading medical technology company that significantly contributes to healthcare improvements worldwide, positively impacting over 100 million patients annually through its comprehensive range of innovative medical products and services.
Stryker announced the successful results of a two-year multicenter trial comparing its InSpace implant to partial repair for massive irreparable rotator cuff tears (MIRCTs), published in the Journal of Bone and Joint Surgery. The study involved 184 patients and demonstrated that InSpace provides effective treatment with early functional recovery, pain relief, and shorter surgical times. This biodegradable implant offers a less invasive alternative for patients, addressing common shoulder dysfunctions, and is positioned as a significant innovation in surgical options for MIRCTs.
Stryker (NYSE:SYK) will take part in the Bank of America Securities 2022 Health Care Conference on May 11, 2022, at 11:00 a.m. Eastern Time. The company will be represented by Andy Pierce, Group President of MedSurg and Neurotechnology, and Preston Wells, Vice President of Investor Relations. Interested parties can access a simultaneous webcast of the presentation on Stryker's website, where it will also be archived for later viewing. Stryker is renowned for its innovative medical technology aimed at enhancing healthcare outcomes.
Stryker reported a strong first quarter of 2022, with net sales increasing 8.1% to $4.3 billion and organic net sales rising 9.2%. The reported EPS increased 6.3% to $0.84, while the adjusted EPS rose 2.1% to $1.97. Despite these positive results, the company acknowledged ongoing challenges from COVID-19 and supply chain issues. For the full year, Stryker anticipates organic net sales growth at the higher end of the 6% to 8% guidance range and adjusted EPS at the lower end of $9.60 to $10.
Stryker (NYSE:SYK) will hold a conference call on April 28, 2022, at 4:30 p.m. ET to discuss its operating results for Q1 2022, following the release of final results at 4:05 p.m. on the same day. Interested participants can register for the call here. A webcast will be available on Stryker's Investor Relations page, with a replay accessible after the call. Stryker is a leading medical technology company focused on improving healthcare outcomes.
Stryker (NYSE:SYK) has scheduled its 2022 Annual Meeting of Shareholders for May 4, 2022, at 9:30 a.m. ET. The meeting will be held virtually, with details available on the Investor Relations page of the company's website. Shareholders can listen in by calling specified numbers. A recording of the meeting will be accessible starting May 5, 2022, until the filing of the definitive proxy statement for the 2023 meeting. Stryker is known for its innovative medical technology solutions across various specialties, aimed at improving healthcare outcomes.
Vocera Communications, Inc. announced a change following its acquisition by Stryker Corporation (NYSE: SYK). As of February 23, 2022, a Fundamental Change has occurred under the indentures governing Vocera’s 1.50% Convertible Senior Notes due 2023 and 0.50% Convertible Senior Notes due 2026. Noteholders can repurchase their Notes for cash at a price of 100% of the principal amount and accrued interest by March 25, 2022. Additionally, noteholders can convert their Notes at an increased rate until March 25, 2022. The Paying Agent is U.S. Bank Trust Company.